Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 4:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 360 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Irritable Bowel Syndrome Clear all
Completed Not applicable Interventional

Comparing Two Types of Diets on Psychological and Gastrointestinal Symptoms

NCT03035799
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Paleolithic diet, General Healthful Diet
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Sep 20, 2026, 4:36 PM EDT
Completed Phase 2 Interventional Results available

Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

NCT00460811
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation
Interventions
Linaclotide Acetate, Matching placebo
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
79
States / cities
Huntsville, Alabama • Chandler, Arizona • Tuscon, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced Sep 20, 2026, 4:36 PM EDT
Completed Phase 4 Interventional Results available

Ability of Mayo Clinic High-performance Liquid Chromatography (HPLC) Method to Measure Fecal Bile Acids

NCT02111603
View directory record Official record
Conditions
Diarrhea Predominant Irritable Bowel Syndrome
Interventions
Colesevelam
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Sep 20, 2026, 4:36 PM EDT
Completed Phase 3 Interventional Results available

Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)

NCT02493452
View directory record Official record
Conditions
Irritable Bowel Syndrome Characterized by Constipation
Interventions
Plecanatide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
191
States / cities
Birmingham, Alabama • Guntersville, Alabama • Huntsville, Alabama + 157 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Sep 20, 2026, 4:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow

NCT00634608
View directory record Official record
Conditions
Allergic Rhinitis, Asthma, Back Pain, Benign Prostatic Hypertrophy, Bursitis, Depression, Anxiety, Diabetes Mellitus, Esophageal Reflux, HIV Infections, Hyperlipidemia, Hypertension, Insomnia, Irritable Bowel Syndrome, Obesity, Osteoporosis (Senile), Shoulder Pain, Sinusitis, Symptomatic Menopause, Urinary Incontinence, Urinary Tract Infection, Vaginitis
Interventions
Health Information Prescription
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Sep 20, 2026, 4:36 PM EDT
Completed Phase 4 Interventional

Effect of Tenapanor on the Metagenomics and Metabolomics of Patients With Irritable Bowel Syndrome With Constipation

NCT05995899
View directory record Official record
Conditions
IBS, IBS - Irritable Bowel Syndrome
Interventions
Tenapanor
Drug
Lead sponsor
Kyle Staller, MD, MPH
Other
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 20, 2026, 4:36 PM EDT
Active, not recruiting Phase 3 Interventional

Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

NCT05643534
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions
Tenapanor 50 MG, Tenapanor 25 mg bid, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
12 Years to 17 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
39
States / cities
Foley, Alabama • Tucson, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 20, 2026, 4:36 PM EDT
Completed Phase 4 Interventional Results available

An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation

NCT02590432
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation, Chronic Idiopathic Constipation
Interventions
Linaclotide
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
79
States / cities
Anniston, Alabama • Athens, Alabama • Childersburg, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Sep 20, 2026, 4:36 PM EDT
Terminated Phase 1 Interventional

Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome

NCT04655599
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Olorinab, Placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced Sep 20, 2026, 4:36 PM EDT
Completed No phase listed Observational

Fecal Calprotectin Collection Protocol

NCT03143517
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Irritable Bowel Syndrome, Ulcerative Colitis, Crohn Disease, Indeterminate Colitis, Chronic Diarrhea, Celiac Disease, Diverticulitis, Abdominal Pain, Distension, Weight Loss, Food Intolerance, Constipation
Interventions
Stool collection
Diagnostic Test
Lead sponsor
DiaSorin Inc.
Industry
Eligibility
4 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
13
States / cities
Dothan, Alabama • Little Rock, Arkansas • Mission Hills, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Sep 20, 2026, 4:36 PM EDT
Not yet recruiting Early Phase 1 Interventional

Psilocybin-Assisted Psychotherapy in Treating Irritable Bowel Syndrome (IBS)

NCT06760533
View directory record Official record
Conditions
IBS - Irritable Bowel Syndrome
Interventions
Psilocybin 25 mg, Psychotherapy Treatment Session, Niacin 100 mg
Drug · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 20, 2026, 4:36 PM EDT
Completed Phase 3 Interventional Results available

Long Term Safety Study of Plecanatide

NCT02706483
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Plecanatide
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
2,272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
204
States / cities
Athens, Alabama • Birmingham, Alabama • Dothan, Alabama + 200 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Sep 20, 2026, 4:36 PM EDT
Completed Not applicable Interventional

Do Biomarkers Predict Response to a Pediatric Chronic Pain Symptom Management Program?

NCT03823742
View directory record Official record
Conditions
Irritable Bowel Syndrome, Functional Abdominal Pain Syndrome, Functional Gastrointestinal Disorders, Functional Bowel Disorder, Functional Abdominal Pain, Functional Abdominal Pain Disorders
Interventions
Cognitive Behavioral Therapy, Low FODMAP Diet
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
7 Years to 12 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 20, 2026, 4:36 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA

NCT05754190
View directory record Official record
Conditions
Chronic Pain, Acute Pain, Post Operative Pain, Fibromyalgia, Primary, Fibromyalgia, Secondary, Fibromyalgia, Irritable Bowel Syndrome, Chronic Headache Disorder, Chronic Migraine, Chronic Pelvic Pain Syndrome, Temporomandibular Joint Disorders, Endometriosis-related Pain, Arthritis, Chronic Low-back Pain, Failed Back Surgery Syndrome, Post Herpetic Neuralgia, Neuropathic Pain, Painful Diabetic Neuropathy, Painful Bladder Syndrome, Trauma-related Wound, Trauma, Multiple, Chronic Pain Syndrome, Chronic Shoulder Pain
Interventions
SOMA pain manager smartphone application
Device
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Sep 20, 2026, 4:36 PM EDT
Completed Phase 3 Interventional Results available

An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation

NCT00730171
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation, Chronic Constipation
Interventions
Linaclotide
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
116
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 106 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2018 · Synced Sep 20, 2026, 4:36 PM EDT
Completed Phase 1 Interventional

Safety Study of Probiotics in Adults With Irritable Bowel Syndrome

NCT00971711
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Probiotic
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 7, 2016 · Synced Sep 20, 2026, 4:36 PM EDT
Completed Not applicable Interventional

Precision Pain Self-Management in Young Adults With Irritable Bowel Syndrome

NCT03332537
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Personalized IBS Pain SM
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years to 29 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Farmington, Connecticut • Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Sep 20, 2026, 4:36 PM EDT
Completed Phase 2 Interventional

Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

NCT00699166
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
DNK333
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older · Female only
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
29
States / cities
Anniston, Alabama • Huntsville, Alabama • Northport, Alabama + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2008 · Synced Sep 20, 2026, 4:36 PM EDT
Completed Phase 1Phase 2 Interventional

Effect of TU-100 in Patients With Irritable Bowel Syndrome (IBS)

NCT01890837
View directory record Official record
Conditions
Irritable Bowel Syndrome, Digestive System Diseases, Gastrointestinal Diseases, Intestinal Diseases, Abdominal Pain
Interventions
Daikenchuto (TU-100), Placebo
Drug
Lead sponsor
Tsumura USA
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 12, 2016 · Synced Sep 20, 2026, 4:36 PM EDT
Completed Phase 3 Interventional Results available

Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation

NCT00948818
View directory record Official record
Conditions
Irritable Bowel Syndrome Characterized by Constipation
Interventions
Linaclotide 290 micrograms, Matching placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
803 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
111
States / cities
Birmingham, Alabama • Hueytown, Alabama • Huntsville, Alabama + 94 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2013 · Synced Sep 20, 2026, 4:36 PM EDT
Completed Phase 2 Interventional Results available

The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)

NCT01722318
View directory record Official record
Conditions
Irritable Bowel Syndrome Characterized by Constipation
Interventions
Plecanatide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
99
States / cities
Birmingham, Alabama • Dothan, Alabama • Glendale, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated May 27, 2019 · Synced Sep 20, 2026, 4:36 PM EDT
Completed Phase 2 Interventional Results available

Mesalamine Granules for Irritable Bowel Syndrome (IBS) With Diarrhea

NCT01177410
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Placebo, Mesalamine Granules 750 mg, Mesalamine Granules 1500 mg
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Sherwood, Arkansas • Anaheim, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Sep 20, 2026, 4:36 PM EDT
Completed Not applicable Interventional

Effects of Low FODMAP Diet on Leaky Gut

NCT04526808
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
FODMAP diet
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 20, 2026, 4:36 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Irritable Bowel Syndrome and Control Volunteers: Diet Challenge

NCT03983434
View directory record Official record
Conditions
IBS - Irritable Bowel Syndrome
Interventions
Inulin
Dietary Supplement
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Sep 20, 2026, 4:36 PM EDT